Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation

Transplant Infectious Disease

Volumn 15, Issue 6, 2013, Pages 551-558

  Posadas Salas, M A ^a   Taber, D J ^a   Chua, E ^a   Pilch, N ^b   Chavin, K ^a   Thomas, B ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cytomegalovirus infection; Renal function; Valganciclovir

Indexed keywords

TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK ASSESSMENT;

CYTOMEGALOVIRUS INFECTION; RENAL FUNCTION; VALGANCICLOVIR;

ADULT; AGED; ANTIBODIES, VIRAL; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; BODY WEIGHT; CREATININE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 84888882484     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12133     Document Type: Article

References (13)

1. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44 (5): 495-507.
2. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
3. Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008; 8: 1297-1302.
4. Perrottet N, Decosterd L, Meylan P, et al. Valganciclovir in adult solid organ recipients. Clin Pharmacokinet 2009; 48 (6): 399-418.
5. Welker H, Farhan M, Humar A, et al. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. Transplantation 2010; 90: 1414-1419.
6. Taber DJ, Pilch NA, Meadows HB, et al. Prospective comparative efficacy of induction therapy in a high-risk kidney transplant population. Am J Transplant 2012; 12 (S3): 57.
7. Winter M, Guhr K, Berg G. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy 2012; 32 (7): 604-612.
8. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing based on body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009; 9: 636-643.
9. Wiltshire H, Paya C, Pescovitz M, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79 (5): 1477-1483.
10. Czock D, Scholle C, Rasche FM, et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142-150.
11. Cochrane A. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients. Am J Health-Syst Pharm 2006; 63: S17-S21.
12. Gruber S, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005; 19: 273-278.
13. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5: 1462-1468.